OKUR OnKure Therapeutics Inc.

Price (delayed)

$4.31

Market cap

$174.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.33

Enterprise value

-$17.59M

?
Relative Growth: Rel. Growth: 1
Relative Strength: Rel. Strength: 85
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5
Highlights
The equity has soared by 103% year-on-year
OKUR's debt has dropped by 57% year-on-year and by 26% since the previous quarter
OKUR's EPS has dropped by 131% year-on-year

Key stats

What are the main financial stats of OKUR

OKUR stock price

How has the OnKure Therapeutics stock price performed over time
Intraday
2.62%
1 week
4.61%
1 month
-6.3%
1 year
49.13%
YTD
48.62%
QTD
4.11%

Financial performance

How have OnKure Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$61.57M
Net income
-$58.75M
Gross margin
N/A
Net margin
N/A
OnKure Therapeutics's operating income has increased by 2.2% from the previous quarter

Price vs fundamentals

How does OKUR's price correlate with its fundamentals

Growth

What is OnKure Therapeutics's growth rate over time

Valuation

What is OnKure Therapeutics stock price valuation
P/E
N/A
P/B
0.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OKUR's EPS has dropped by 131% year-on-year
The equity has soared by 103% year-on-year
The P/B is 66% less than the 5-year quarterly average of 0.9 and 38% less than the last 4 quarters average of 0.5

Efficiency

How efficient is OnKure Therapeutics business performance
OKUR's ROA is up by 25% since the previous quarter and by 12% year-on-year
OKUR's ROE is up by 25% since the previous quarter and by 11% year-on-year

Dividends

What is OKUR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OKUR.

Financial health

How did OnKure Therapeutics financials performed over time
The total liabilities has soared by 142% QoQ and by 55% YoY
OnKure Therapeutics's total assets has surged by 99% YoY
OKUR's debt is 100% smaller than its equity
The equity has soared by 103% year-on-year
OnKure Therapeutics's debt to equity has plunged by 100% from the previous quarter and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.